Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleTeaching Case Studies
Open Access

Effect of COVID-19 on 18F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning 18F-FDG PET/CT for Oncologic Evaluation?

Anwin Joseph Kavanal, Santosh Ranjan Jena, Rajender Kumar, Chandan Krushna Das, Sunil Kumar and Bhagwant Rai Mittal
Journal of Nuclear Medicine Technology September 2021, 49 (3) 284-285; DOI: https://doi.org/10.2967/jnmt.121.262145
Anwin Joseph Kavanal
1Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santosh Ranjan Jena
1Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajender Kumar
1Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandan Krushna Das
2Medical Oncology OPD, Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunil Kumar
1Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhagwant Rai Mittal
1Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Incidental detection of coronavirus disease 2019 (COVID-19)–related lung changes on 18F-FDG PET/CT images of oncology patients has been increasingly reported. Most of the case reports or series have stressed the retrospective diagnosis of COVID-19 with the help of 18F-FDG PET/CT lung findings. In this case report, we introduce a different aspect of COVID-19–related lung changes on 18F-FDG PET/CT, interfering with the evaluation of metastatic lung lesions in a patient with renal cell carcinoma.

  • COVID-19
  • 18F-FDG PET/CT
  • lung metastasis
  • response evaluation
  • renal cell carcinoma

Various lung involvement patterns have been reported on 18F-FDG PET/CT scans of coronavirus disease 2019 (COVID-19) patients undergoing workup for various malignancies. The patterns range from 18F-FDG–avid diffuse ground-glass opacities to 18F-FDG–avid patchy consolidatory changes, with or without 18F-FDG–avid mediastinal lymph nodes, depending on the imaging time from the onset of infection and other unknown factors (1–4). COVID-19 infection was a retrospective diagnosis in most reported cases, after the typical findings were seen on the 18F-FDG PET/CT images (3–7). Here, we present a different aspect of COVID-19 on 18F-FDG PET/CT, in which there was interference with response assessment in a patient receiving chemotherapy for pulmonary metastasis from renal cell carcinoma.

CASE REPORT

A 45 y-old man with a known case of metastatic renal cell carcinoma underwent cytoreduction nephrectomy followed by first-line chemotherapy with pembrolizumab and axitinib because of multiple cannonball metastases in the lungs. 18F-FDG PET/CT at the end of treatment showed disease progression in the form of an increase in the number and size of lung nodules. The patient was then started on second-line chemotherapy with oral lenvatinib (18 mg daily) and everolimus (5 mg daily). His interim 18F-FDG PET/CT scan (Fig. 1) showed a favorable response (>30% reduction in size and 18F-FDG avidity compared with baseline PET/CT) to second-line therapy, and he was continued on the same treatment. He was diagnosed with COVID-19 in May 2020 on evaluation for malaise and chills. He was managed conservatively with antibiotics, antipyretics, and multivitamins in a local hospital. He had no symptoms or signs suggestive of pneumonia and never required oxygen support during the 11-d course in the hospital. He was discharged from the hospital after a negative nucleic acid test 1 wk before he was scheduled for an 18F-FDG PET/CT scan at 6 mo of chemotherapy to determine the response. The 18F-FDG PET/CT scan (Fig. 2) showed 18F-FDG–avid diffuse ground-glass opacities/patchy consolidatory changes bilaterally in the lung fields from apex to base, obscuring the metastatic lesions. The COVID-19–related lung changes obscured both the anatomic and the metabolic features of the metastatic lesions, leading to difficulty in assessing the response to treatment.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

18F-FDG PET/CT whole-body maximum-intensity-projection image (A), axial PET/CT images (B), and corresponding CT images (C) showing variably 18F-FDG–avid random nodules in both lung fields (SUVmax of hottest nodule, 9.9).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

18F-FDG PET/CT whole-body maximum-intensity-projection image (A), axial PET/CT images (B), and corresponding CT images (C) showing 18F-FDG–avid diffuse ground-glass opacities/patchy consolidatory changes bilaterally in lung fields from apex to base, obscuring details of metastatic lesions (SUVmax of hottest nodule, 7.8; SUVmax of ground-glass opacities, 7.3).

DISCUSSION

18F-FDG uptake in ground-glass opacities in the background may add spill-in counts to metastatic lesions, causing a falsely high uptake in metastatic lesions (8). For this reason, an accurate assessment of the metabolic response was not possible in this patient. The patient was advised to repeat the nucleic acid test because of 18F-FDG avidity in the ground-glass opacities/consolidatory changes and was found to be positive. The patient was then advised to remain home in isolation again.

CONCLUSION

During the COVID-19 pandemic phase, we have to consider sources of possible interference such as described in this report before scheduling patients for 18F-FDG PET/CT scans for various oncologic purposes.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online July 9, 2021.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

REFERENCES

  1. 1.↵
    1. Ajuria-Illarramendi O,
    2. Martinez-Lorca A,
    3. Orduna-Diez MDP.
    [18F]FDG-PET/CT in different COVID-19 phases. IDCases. 2020;21:e00869.
    OpenUrl
  2. 2.
    1. Charters PFP,
    2. Little D,
    3. Rodrigues JCL,
    4. et al
    . 18FDG-PET/CT findings in COVID-19: a single centre retrospective radiological review. BJR Case Rep. 2020;6:20200091.
    OpenUrl
  3. 3.↵
    1. Liu C,
    2. Zhou J,
    3. Xia L,
    4. et al
    . 18F-FDG PET/CT and serial chest CT findings in a COVID-19 patient with dynamic clinical characteristics in different period. Clin Nucl Med. 2020;45:495–496.
    OpenUrl
  4. 4.↵
    1. Colandrea M,
    2. Gilardi L,
    3. Travaini LL,
    4. et al
    . 18F-FDG PET/CT in asymptomatic patients with COVID-19: the submerged iceberg surfaces. Jpn J Radiol. 2020;38:1007–1011.
    OpenUrl
  5. 5.
    1. Deng Y,
    2. Lei L,
    3. Chen Y,
    4. et al
    . The potential added value of FDG PET/CT for COVID-19 pneumonia. Eur J Nucl Med Mol Imaging. 2020;47:1634–1635.
    OpenUrl
  6. 6.
    1. Doroudinia A,
    2. Tavakoli M.
    A case of coronavirus infection incidentally found on FDG PET/CT scan. Clin Nucl Med. 2020;45:e303–e304.
    OpenUrl
  7. 7.↵
    1. Martineau P,
    2. Kidane B.
    FDG PET/CT findings in an asymptomatic case of confirmed COVID-19. Clin Nucl Med. 2020;45:647–648.
    OpenUrl
  8. 8.↵
    1. Akerele MI,
    2. Wadhwa P,
    3. Silva-Rodriguez J,
    4. et al
    . Validation of the physiological background correction method for the suppression of the spill-in effect near highly radioactive regions in positron emission tomography. EJNMMI Phys. 2018;5:34.
    OpenUrl
  • Received for publication February 16, 2021.
  • Accepted for publication March 26, 2021.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 49 (3)
Journal of Nuclear Medicine Technology
Vol. 49, Issue 3
September 1, 2021
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of COVID-19 on 18F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning 18F-FDG PET/CT for Oncologic Evaluation?
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Effect of COVID-19 on 18F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning 18F-FDG PET/CT for Oncologic Evaluation?
Anwin Joseph Kavanal, Santosh Ranjan Jena, Rajender Kumar, Chandan Krushna Das, Sunil Kumar, Bhagwant Rai Mittal
Journal of Nuclear Medicine Technology Sep 2021, 49 (3) 284-285; DOI: 10.2967/jnmt.121.262145

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effect of COVID-19 on 18F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning 18F-FDG PET/CT for Oncologic Evaluation?
Anwin Joseph Kavanal, Santosh Ranjan Jena, Rajender Kumar, Chandan Krushna Das, Sunil Kumar, Bhagwant Rai Mittal
Journal of Nuclear Medicine Technology Sep 2021, 49 (3) 284-285; DOI: 10.2967/jnmt.121.262145
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Once Again--The SNMMI "Nailed It"!
  • Google Scholar

More in this TOC Section

  • High-Sensitivity Troponin Elevation in a Young Woman with Typical Chest Pain: The Heart of the Matter
  • Pulmonary Adenocarcinoma Revealed by Parathyroid Scintigraphy: An Incidental Case to Remember
  • Prominent Right Ventricular Tracer Uptake: A Harbinger of Multivessel Coronary Artery Disease
Show more Teaching Case Studies

Similar Articles

Keywords

  • COVID-19
  • 18F-FDG PET/CT
  • lung metastasis
  • response evaluation
  • renal cell carcinoma
SNMMI

© 2025 SNMMI

Powered by HighWire